Results 81 to 90 of about 8,230 (206)
New Horizons for Multiple Sclerosis Therapy: 2025 and Beyond
Annals of Neurology, Volume 98, Issue 2, Page 317-328, August 2025.The advances achieved against multiple sclerosis (MS) represent one of the great success stories of modern molecular medicine. The development of therapies with increasing selectivity and safety, guided by gains in understanding the fundamental immunology, neurobiology, genetics, and triggers of this disease, have broadened the traditional focus on ...
Joseph J. Sabatino Jr. +2 more
wiley +1 more source
Psycho-Oncology, Volume 34, Issue 6, June 2025.ABSTRACT Objective Young adults (YAs) undergoing hematopoietic stem cell transplantation (HSCT) often face significant transplant‐related morbidity and mortality. Advance care planning (ACP) discussions can provide YAs with the opportunity to address treatment goals and care preferences with their family members and healthcare team.
Anna Katharina Vokinger +8 more
wiley +1 more source
Chapter Three. EED library as a basis for systematic reviews [PDF]
, 2016 3.1 Defining Systematic Review Question Priorities 3.2 Determining Relevance to the Systematic Review 3.3 Acquisition of References and Copyright Fair Use Compliance 3.4 Documenting Relevance to the Systematic Review 3.5 Data Extraction for the ...
Denno, Donna M +4 more
core +1 more source
Subcutaneous Immunoglobulin-G Replacement Therapy with Preparations Currently Available in the United States for Intravenous or Intramuscular Use: Reasons and Regimens [PDF]
, 2005 For patients who require replacement therapy for primary immunodeficiency, subcutaneous infusions of immunoglobulin G (IgG) may be preferable to intravenous infusions for several reasons.
Akhilesh Chouksey +3 more
core +2 more sources
Journal of Clinical Ultrasound, Volume 53, Issue 4, Page 612-619, May 2025.The study subjects were mainly CRC patients (n = 120), all of whom underwent the same comprehensive treatment regimen and were divided into the effective treatment group (n = 86) and the ineffective treatment group (n = 34) according to efficacy after treatment.
Hong‐Bo Ji +4 more
wiley +1 more source
Differential in vitro infection of neural cells by astroviruses [PDF]
, 2019 Encephalitis remains a diagnostic conundrum in humans as over 50% of cases are managed without the identification of an etiology. Astroviruses have been detected from the central nervous system of mammals in association with disease, suggesting that this
Janowski, Andrew B +2 more
core +2 more sources
Beyond TREC: Pivotal role of tandem TREC/KREC assay in Czech SCID NBS pilot programme
Pediatric Allergy and Immunology, Volume 36, Issue 5, May 2025.Abstract Background Severe combined immunodeficiency (SCID) is a fatal but treatable inborn error of immunity (IEI). Newborn screening (NBS) using T‐cell receptor excision circles (TREC) has been adopted globally, with very few countries incorporating kappa recombination excision circles (KREC) to also detect early B‐cell development disorders, such as
Markéta Bloomfield +23 more
wiley +1 more source
Clinical and Genetic Study of X-linked Agammaglobulinemia Patients (The Benefit of Early Diagnosis)
Iranian Journal of Allergy, Asthma and Immunology, 2020 X-linked agammaglobulinemia (XLA) is a primary immunodeficiency caused by genetic defects in the Bruton tyrosine kinase (Btk) gene. XLA is characterized as an antibody deficiency by recurrent bacterial infections, the absence of peripheral B cells, and ...
Zahra Alizadeh +9 more
doaj +1 more source
Lung disease in primary antibody deficiency. [PDF]
, 2015 This Review summarises current knowledge on the pulmonary manifestations of primary antibody deficiency (PAD) syndromes in adults. We describe the major PAD syndromes, with a particular focus on common variable immunodeficiency (CVID).
Grimbacher, B, Hurst, JR, Verma, N
core +1 more source
Long-term efficacy and safety of Hizentra® in patients with primary immunodeficiency in Japan, Europe, and the United States: a Review of 7 Phase 3 Trials [PDF]
, 2018 Many patients with primary immunodeficiency (PID) require immunoglobulin G (IgG) replacement therapy, delivered as intravenous IgG (IVIG) or subcutaneous IgG (SCIG). We aim to identify trends in efficacy and safety that would not be evident in individual
Borte, Michael +8 more
core +2 more sources